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Abstract Familial transthyretin (TTR) amyloidosis is caused
by a mutation in the TTR gene, although wild-type (wt) TTR
is also incorporated into the amyloid fibrils. Liver transplan-
tation (LT) is the prevailing treatment of the disease and is
performed in order to eliminate the mutant TTR from plasma.
The outcome of the procedure is varied; especially problem-
atic is a progressive cardiomyopathy seen in some patients,
presumably caused by continued incorporation of wtTTR.
What determines the discrepancy in outcome is not clear. We
have previously shown that two structurally distinct amyloid
fibrils (with or without fragmented ATTR) are found among
ATTRV30M patients. In this study, we investigated the
proportion of wtATTR in cardiac and adipose amyloid from
patients having either fibril type. It was found that cardiac
amyloid more easily incorporates wtTTR than adipose
amyloid, offering a potential explanation for the vulnerability
ofcardiactissueforcontinuedamyloidosisafterLT.Incardiac
tissue, fibrils with fragmented ATTR contained a higher wt
proportion than fibrils without, suggesting that continued
incorporationofwtTTRafterLT,perhaps,cantakeplacemore
easilyinthesepatients.Inadiposetissue,arapidincreaseinwt
proportion after LT indicates that a rather fast turnover of the
deposits must occur. A difference in wt proportion between
the fibril types was seen post-LT but not pre-LT, possibly
caused by differences in turnover rate. Conclusively, this
study further establishes the basic dissimilarities between the
twofibriltypesanddemonstratesthattheirroleinLToutcome
needs to be further investigated.
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Introduction
Amyloidoses are a group of diseases characterized by
aggregation of proteins into a stable fibrillar structure that
accumulates in tissues. Familial transthyretin (TTR) amy-
loidosis is a lethal systemic disease caused by a mutation in
the gene coding for the plasma transporter TTR. Around
100 amyloidogenic mutations have been found to date [1].
The mutation renders the protein more prone to form
amyloid, but the wild-type (wt) protein is also amyloido-
genic and is incorporated into the fibrils of heterozygotes
[2–4]. Moreover, in senile systemic amyloidosis, wtTTR is
the only fibrillar protein [5]. The main features of the
familial forms are polyneuropathy and/or cardiomyopathy,
but the clinical picture is highly varied between mutations
and also between patients with the same mutation [6, 7].
The reason(s) behind the clinicopathological differences
between patients is/are far from understood, not only in
ATTR amyloidosis (nomenclature according to [8]), but in
all systemic variants of amyloid disease. In a previous study
on Swedish ATTRV30M patients, we found that in some of
the individuals, the amyloid fibrils contain a mixture of full-
length and fragmented ATTR (fibril type A) while in other
patients the fibrils are composed of only full-length ATTR
(fibril type B)[9]. The vast majority of the fragmented
E. Ihse:P. Westermark (*)
Department of Genetics and Pathology, Uppsala University,
Rudbeck laboratory,
75185, Uppsala, Sweden
e-mail: Per.Westermark@genpat.uu.se
O. B. Suhr
Department of Internal Medicine, Umeå University,
901 85, Umeå, Sweden
U. Hellman
Ludwig Institute for Cancer Research, Ltd, Uppsala University,
Box 595, 751 24, Uppsala, Sweden
J Mol Med (2011) 89:171–180
DOI 10.1007/s00109-010-0695-1ATTR species found in fibril type A has been found to be
N-terminally truncated and starts at positions around amino
acid residue 50 while only very small amounts of C-
terminally truncated fragments are found [9–11]. The fibril
type seems to be consistent between different organs within
an individual [12]. We further discovered that the fibril type
was correlated with the clinical phenotype of the patients;
individuals with fragmented ATTR present in the fibrils had
a late onset of disease and an enlarged heart due to heavy
amyloid deposition while patients having fibrils without
fragments had an early disease onset and much smaller
amyloid amounts in cardiac tissue [12].
Liver transplantation (LT) is performed on ATTR
amyloidosis patients, as this removes the main production
site of the mutant protein [13, 14]. In many cases, the
progress of amyloid deposition and neurological symptoms
seems to halt or slow down after transplantation, and some
patients also show an improvement; however, for other
patients the symptoms have worsened [14, 15]. Especially
problematic is the fact that in some transplanted individu-
als, a rapid continued deposition is taking place in cardiac
tissue, presumably caused by the addition of wtTTR to the
amyloid [16, 17]. Mostly, this has been seen in patients
with other mutations than V30M [18, 19], but progression
of cardiac amyloidosis has been reported to occur also in
some V30M patients [20–23]. The special vulnerability of
heart tissue for continued deposition after transplantation
and the reason why some patients benefit from the
procedure, whereas amyloid progression is triggered in
others, are not understood. In order to be able to select
patients that are suitable for the operation, it is highly
important to define the factor(s) determining the outcome of
the transplantation.
We hypothesize that amyloid in cardiac tissue more easily
incorporates wtTTR than amyloid in other organs and that the
cardiac depositstherefore are moreprone tocontinuegrowing
after liver transplantation. We also theorize that the two fibril
composition types found inATTRV30Mpatients(presence of
fragmented ATTR or not) differ in their propensity to
incorporate wtTTR molecules and that this is a factor that
could affect the outcome of transplantation. In this study, we
therefore investigated the proportion of wild-type ATTR in
cardiac and adipose amyloid from ATTRV30M patients,
having fibrils of type A or B.
Material and methods
Tissue material and patients
All patients in the study have been diagnosed with familial
ATTR amyloidosis and were heterozygous for the mutation
ATTRV30M. The patients originated from the same
geographical area in northern Sweden. Duration of disease
was estimated anamnestically.
Heart tissue was obtained from 12 patients at autopsy, of
whom one had undergone liver transplantation. Abdominal
subcutaneous adipose tissue biopsy was taken from 32
patients, of whom 20 were liver transplanted. These 32
patients were not the same individuals from whom the heart
tissue was obtained, except for two cases. Patient data are
displayed in Tables 1 and 2. The study was approved by the
ethical committees of Umeå University Hospital and
Uppsala University Hospital and was performed in accor-
dance with the 1964 Declaration of Helsinki. Informed
consent was obtained from all subjects.
Tissue preparation
Heart tissue was either stored at −20°C or fixed in formalin
and embedded in paraffin. The amyloid was extracted from
the frozen tissue as described [9]. In short, the tissue was
repeatedly homogenized in 0.15 M NaCl and 0.05 M sodium
citrate and centrifuged before washing in distilled water
several times. The resulting pellet was lyophilized, defatted
in acetone, and left to dry. The samples were dissolved in a
solution of 6 M guanidine–HCl, 0.1 M Tris–HCl, pH 8.0,
and 0.1 M dithiothreitol (DTT) for 4 days, followed by
centrifugation. The supernatant was dialyzed against saturat-
ed ammonium sulfate followed by distilled water and the
sample was thereafter lyophilized. To extract amyloid from
paraffin-embedded tissue, 10-μm sections were deparaffi-
nized, scraped off the slides, and pooled [24]. The material
was dissolved in guanidine–HCl with DTT, dialyzed, and
lyophilized as described for the frozen tissue.
Subcutaneous adipose tissue obtained through biopsy
was cut into smaller pieces, rinsed in 0.15 M NaCl with
0.02% sodium azide several times, and incubated in a
0.88% ammonium chloride solution for lysis of erythro-
cytes. The material was thereafter washed in distilled water
and defatted in acetone for several changes and allowed to
dry [25]. Where enough biopsy tissue was available, some
of the dry material was dissolved in guanidine–HCl with
DTT, dialyzed, and lyophilized as described above.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and Western blot analysis
The tissue materials, either heart or adipose tissue, were
dissolved in a sample buffer containing 4% sodium dodecyl
sulfate (SDS), 0.02 M of DTT, and 0.06 M of iodoaceta-
mide and separated in a 16% gel using a Tris–tricine system
[26]. The protein bands were visualized by staining with
Coomassie Brilliant Blue.
For Western blot, the samples were transferred to a
Hybond-ECL nitrocellulose membrane (GE Healthcare,
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against TTR50–127 and TTR24–35 were used as primary
antibodies (characterized in [27] and [28]). Swine anti-
rabbit antibodies conjugated with horseradish peroxidase
(Dako, Glostrup, Denmark) were used as secondary
antibody. The reaction was visualized with an enhanced
chemiluminescence system (GE Healthcare).
Analysis by matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry
Bands shown by Western blot to correspond to full-length
monomeric ATTR, at approximately 15 kDa, and frag-
mented ATTR, at approximately 5–10 kDa, were cut out
from the Coomassie Brilliant Blue-stained gels. Trypsin
was used to digest the proteins into peptides as described
[29], and these were analyzed by matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometry (Ultraflex III TOF/TOF; Bruker Daltonics,
Bremen, Germany). The spectrum peaks corresponding to
the tryptic peptides consisting of amino acid residues 22–34
were investigated. Other tryptic peptides containing amino
acid residue 30, which would have resulted from incom-
plete cleavage, were searched for but were not seen. The
height of the peaks was taken as a measure of relative
quantity. As the methionine in the mutant variant may
become oxidized, the height of the peaks corresponding to
the mutant peptide in non-oxidized (MH
+=1,398.732) and
mono-oxidized (sulfoxide) state (MH
+=1,414.726) was
combined to achieve a quantitative value of the mutant
peptide. The peak corresponding to the di-oxidized (sulfone)
state (MH
+=1,430.722) was either absent or negligible in
size. The wild-type peptide contains no methionine and
gives rise to only one peak (MH
+=1,366.759). The
proportion of wt to total ATTR was calculated.
For samples where enough material was present, gel
electrophoresis and mass spectrometry analysis was repeat-
ed, up to three times if possible, and a mean value was
calculated.
Statistical analysis
Data are reported as mean±SD. Statistical analyses were
performed using non-parametrical methods. The Mann–
Whitney test was used to compare patient groups or tissue
types. The Wilcoxon matched pairs test was used when
Table 1 Clinical data of patients and proportion of wt to total ATTR in cardiac tissue
Patient no. Sex Age at onset of
symptomatic
disease (years)
Duration of
symptomatic
disease (years)
Duration after
LT (years)
wtATTR proportion [mean (range), %]
Homogenized Paraffin-embedded
Intact ATTR Fragmented
ATTR
Intact ATTR Fragmented
ATTR
Fibril type A (fragmented ATTR present)
Pre-LT
1 M 69 5.5 – 73 (68–77) 78 (74–82) 74 (65–80) 79 (77–81)
2 M NK NK – 69 (65–75) 77 (77–78) NA NA
3 F NK NK – 72 (69–74) 76 (73–78) 72 (68–76) 77 (68–85)
4 M NK 13 – 73 (71–75) 79 70 81
5 M 62 13 – 75 (74–76) 85 (82–88) 75 (69–84) 81 (76–89)
6 M NK NK – 74 (71–79) 79 (73–84) 74 (71–77) 79 (78–79)
Mean±SD 65±3.5 10±3.5 – 73±2.1 79±3.5 73±2.0 79±1.7
Post-LT
7 M 65 10 7 96 (95–97) 97 (96–98) NA NA
Fibril type B (fragmented ATTR not present)
Pre-LT
8 F 52 10 – 43 (40–45) – NA –
9F 4 6 1 1 – 52 (51–54) – 53 (50–57) –
10 F NK NK – 51 (49–52) – 59 (54–63) –
11 NK NK NK – 57 (54–60) – NA –
12 M NK NK – 57 (55–59) – 52 –
Mean±SD 49±4.2 10.5±0.7 – 52±5.7 – 55±3.8 –
NK not known, NA not available
J Mol Med (2011) 89:171–180 173Table 2 Clinical data of patients and proportion of wt to total ATTR in adipose tissue
Patient
no.
Sex Age at onset of
symptomatic
disease (years)
Duration of
symptomatic
disease (years)
Duration after LT
(years)
wtATTR proportion [mean (range), %]
Not guanidine-treated Guanidine-treated
Intact
ATTR
Fragmented
ATTR
Intact
ATTR
Fragmented
ATTR
Fibril type A (fragmented ATTR present)
Pre-LT
1 M 69 5.6 − 48 (42–52) 67 (58–74) 60 (59–61) 63 (62–64)
13 M 67 3.9 − 28 (27–29) 39 (38–39) NA NA
14 M 65 6.4 − 35 (31–39) 50 (48–51) NA NA
15 F 80 4.1 − 34 59 55 (54–56) 64 (55–73)
16 M 63 0.9 − 14 20 NA NA
17 M 68 4.7 − 18 Signal too weak NA NA
18 M 49 9.5 − 36 (30–41) 32 (26–37) NA NA
19 M 68 2.1 − 55 58 52 52
20 M 67 3.2 − 79 (73–85) 79 (70–87) 80 (75–85) 85 (83–87)
21 M 59 3.4 − 18 24 17 (14–21) 22 (18–25)
Mean±SD 66±7.9 4.4±2.4 − 37±20 48±20 53±23 57±23
Post-LT
7 M 65 7.9 4.9 99 (98–
100)
99 (99–99) 100 (99–
100)
96 (95–96)
18 M 49 12.5 2.4 97 (96–98) 85 95 (94–96) 83 (83–83)
21 M 59 5.4 0.6 77 72 NA NA
22 M 63 4.6 3.1 98 (97–98) 94 (90–97) 99 (98–99) 92 (91–94)
23 M 53 6.5 4.0 99 (99–99) 98 (98–98) NA NA
24 F 50 14.4 5.1 100 (99–
100)
96 (96–96) 98 (98–
98)
a 95 (92–97)
Mean±SD 57±6.8 8.6±4.0 3.4±1.7 95±8.9 91±10 98±2.2 92±5.9
Fibril type B (fragmented ATTR not present)
Pre-LT
25 M 30 3.3 – 47 – NA –
26 M 63 1.6 – 28 (26–30) – NA –
27 F 45 4.2 – 35 (31–38) – 31 (20–36) –
28 F 40 1.6 – 36 – NA –
29 M 36 1.7 – 24 – 31 (31–31) –
30 M 30 1.1 – 24 – 34 (29–37) –
31 M 52 2.4 – 42 – 43 (40–45) –
32 F 62 2.4 – 40 (34–48) – NA –
33 F 60 4.9 – 37 – NA –
Mean±SD 46±13 2.6±1.3 – 35±8.0 – 35±5.7
Post-LT
26 M 63 5.4 3.4 76 (69–82) – NA –
27 F 45 6.8 2.0 81 (79–83) – 74 (68–78) –
28 F 40 5.4 3.1 73 (71–74) – 70 (66–73) –
29 M 36 5.2 3.3 71 (66–75) – 65 –
31 M 52 5.9 2.7 77 (74–80) – 84 −
34 F 31 15.3 6.3 63 (56–70) – 46 (43–51) –
35 F 60 9.6 6.7 97 (95–99) – 76 (73–78) –
36 M 60 5.6 3.1 81 (72–89) – NA –
37 M 37 6.1 2.2 66 (62–69) – NA –
38 M 26 12.6 10.6 81 (73–88) – 64 (61–68) –
39 M 48 17.6 13.6 99 (98–99) – NA –
40 M 66 6.9 4.5 78 (75–80) – NA –
41 F 43 9.5 6.9 95 (94–95) – 89 (89–89) –
42 F 60 10.6 6.1 95 – 79 (72–83) –
Mean±
SD
48±13 8.8±4.0 5.3±3.4 81±12 – 72±13 –
NA not available
aThe materialtreatedwith guanidinewasobtained froma biopsytaken6 monthsearlierthan thebiopsyfromwhere the notguanidine-treatedtissuewas obtained.
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patients [guanidine–HCl-treated versus guanidine–HCl-un-
treated adipose tissue as well as frozen and homogenized
versus formalin-fixed and paraffin-embedded (FFPE)
heart tissue]. Spearman’s correlation was used to calcu-
late correlations. P≤0.05 was considered significant. All
tests were performed with the use of the GraphPad Prism
5s o f t w a r e .
Results
Heart tissue
The fibril composition type was determined for each sample
by Western blot using an antiserum against TTR50–127 (see
Fig. 1). The proportion of wt to total ATTR was determined
by MALDI-TOF mass spectrometry (Figs. 2 and 3). The
results from the protein bands on SDS-polyacrylamide gels
corresponding to monomeric full-length ATTR are described
here while the results of the fragmented ATTR species are
presented separately below.
Frozen heart tissue obtained at autopsy from 12 Swedish
patientswiththeV30Mmutation,whohadnot undergoneliver
transplantation, was homogenized and analyzed (see Table 1
for details). Individuals with fibril type A had a clearly higher
proportion of wild-type molecules than patients with type B
(73±2.1% to 52±5.7%, p=0.008). Unfortunately, we only
had access to cardiac tissue from one transplanted patient.
This patient had a fibril composition of type A and the wt
proportion was determined to be 96%, which is noticeably
higher than in any of the non-transplanted patients.
To confirm that the wtATTR proportions obtained was
not affected by the storage or extraction method used, FFPE
tissue was also analyzed for patients where such material
was available (see Table 1). No significant difference in
wild-type proportion was seen for the FFPE tissue
compared to the frozen and homogenized tissue, regardless
if the fibril type groups were analyzed separately (p=1.0 for
type A and p=0.75 for type B) or combined (p=1.0).
Adipose tissue
Subcutaneous fat biopsies were obtained from 32 patients
(see Table 2 for details). For seven individuals, biopsies
were available from both before and after transplantation.
For the other patients, the tissue material was either from
pre or posttransplantation.
Comparisonofwild-typeATTRproportionbetweenfibriltypes
The wild-type proportion of the monomeric full-length
ATTR molecules was determined as described for the
cardiac amyloid. The results of the fragmented species are
presented separately below. In both fibril composition
groups, the proportion of wtATTR was significantly higher
among the LT patients than the non-LT patients (95±8.9%
compared to 37±20%, p=0.002 for type A and 81±12%
compared to 35±8.0%, p=0.0001 for type B) (Fig. 4). For
the seven individuals where biopsies were available both
pre and posttransplantation, a large increase in wt propor-
tion was seen after LT in each case. Amongnon-LTpatients,
there was no difference in mean value of wt proportion
betweenthe twofibriltypes (37±20% comparedto35±8.0%,
p=0.74), although the values were more spread among those
with type A; however, among the LT patients, individuals
with type A had a higher wt proportion than patients with
type B (95±8.9% compared to 81±12%, p=0.02). In fact,
fibrils of type A showed an almost complete dominance of
wtATTR (in all cases but one patient, who had been
transplanted very recently) while the patients lacking frag-
ments had a more varied distribution of wt proportion.
Because of the limited size of many of the adipose
biopsies, the tissue was not dissolved in any amyloid
breaking agent besides SDS. To exclude the possibility that
only parts of the amyloid was dissolved and the results
therefore unrepresentative of the amyloid mass as a whole,
a portion of the tissue was dissolved in guanidine–HCl, for
patients where enough material was available (see Table 2).
There was no statistically significant difference between the
results obtained with or without guanidine–HCl treatment
whenallpatientgroupswerecombined(p=0.31). Neither was
a difference seen when each patient group was compared
separately, except for the group of transplanted patients with
fibril type B (p=0.50 for pre-LT type A, p=0.38 for pre-LT
type B, p=0.58 for post-LT type A and p=0.04 for post-LT
type B). In this group, the values of the guanidine–HCl-
treated samples were slightly lower than those not treated
with guanidine–HCl (mean difference=−10% units).
Wild-type ATTR proportion in relation to other factors
As it seems likely that the time elapsed between transplan-
tation and time of biopsy can affect the proportion of
wtATTR, it was investigated if patients with fibril type A in
general had a longer duration after transplantation than
patients with type B. Such association was not seen (3.4±
1.7 years after LT among type A patients compared to 5.3±
3.4 years among type B patients, p=0.30). When patients
with a similar duration but different fibril type are
compared (Fig. 5), it is even clearer that duration after LT
isnotthereasonforthehigherwtproportionamongfibriltype
A patients. A possible correlation between wt proportion and
durationafterLTisseenwithineachfibriltypegroup(r=0.99,
p=0.03 for type A and r=0.52, p=0.05 for type B), but not
when both groups are combined (r=0.36, p=0.12).
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transplantation were also investigated for potential correla-
tions to wild-type proportion, but none was found (data not
shown).
Comparison of adipose and cardiac amyloid
Among non-LT patients, heart amyloid contained a higher
proportion of wtATTR than adipose amyloid (73±2.1%
compared to 37±20%, p=0.01 among fibril type A and 52±
5.7% compared to 35±8.0%, p=0.005 among type B).
Proportion of wild-type ATTR among fragmented species
The wild-type proportion among the truncated ATTR
molecules was investigated for the patients where such
species were present (fibril type A). Unfortunately, the vast
majority of the fragmented species starts at positions around
amino acid residue 50 while the fragments containing
position 30 seem to be present in the fibrils in only very
small amounts [9, 10]. Western blot with an antiserum
recognizing TTR24–35 was used to find fragments con-
taining amino acid residue 30. Weak reactions could be
seen at sizes of around 10 and 5 kDa (see Fig. 1). The
whole area of approximately 5–10 kDa on the SDS gels
was cut out and analyzed with mass spectrometry.
Overall, there was a rather good agreement between the
wild-type proportion among the full-length and the frag-
mented ATTR molecules in both cardiac and adipose
amyloid (r=0.94, p=0.0001, Fig. 6). A tendency for a
slightly higher wild-type proportion among the fragmented
than among the full-length ATTR can be noted in samples
from non-transplanted patients, whereas the opposite seems
to be true for specimens from transplanted patients.
Discussion
It has been proven difficult to halt amyloid progression by
liver transplantation, as the wtTTR also is amyloidogenic
[5] and apparently continues to be incorporated into the
fibrils even when virtually all variant TTR has been
eliminated from the plasma. Such development was first
discovered in heart tissue [2, 16, 17], as some patients
showed a troublesome increase in cardiac amyloid load
after the procedure [18]. Lately, an increase in wtATTR
proportion after liver transplantation has been found also in
amyloid from kidney [16], nerve [4], and adipose tissue [3]
but, at least for the adipose tissue, the higher wild-type
proportion was said not to be accompanied by a progression
of the deposits. In the present study, we also saw an
increase in wtATTR proportion after transplantation in
adipose amyloid. These observations show that continued
incorporation of wtTTR is not restricted to cardiac tissue;
however, why the heart is especially prone to develop a
progressive disease and why this is not a problem in all
patients is far from understood.
Cardiac versus adipose amyloid
It is not possible to discern from earlier studies if there is a
variation in wild-type proportion in amyloid from different
tissue types, as these studies are rare and most often are
based on only one type of tissue, a single individual,
different mutations, or various purifying and analyzing
techniques. The reported values are also quite diverse; 30–
65% for cardiac amyloid [2, 11, 17, 30, 31], 0–35% for
kidney [16, 32], 35–40% for nerve [4], and 30–50% for
subcutaneous fat tissue [3].
In an attempt to learn if cardiac tissue diverges from other
organsregardingthepropensitytoincorporatewtTTRintothe
amyloid fibrils, we compared the proportion wtATTR in
cardiac to adipose amyloid in non-transplanted patients. The
result clearly showed a higher wtATTR percentage in heart
than adipose tissue, thus suggesting that cardiac amyloid is
especially prone to incorporate wtTTR molecules. This could
be a reason for why the heart is especially vulnerable to
progression of amyloid deposits after transplantation, when
only wt molecules are available.
Impact of fibril type
We have earlier reported that two compositionally and
morphologically distinct fibrils are seen in patients with
Fig. 1 The two fibril composition types,shown bySDS-polyacrylamide
gel electrophoresis (PAGE) and Western blot analyses on adipose tissue.
Lanes 1–4 show a fibril composition of both full-length and fragmented
ATTR (fibril type A) while lanes 5–6 show a fibril composition of only
full-length ATTR (fibril type B). Lanes 1 and 5=Coomassie Blue-
stained SDS-PAGE gels; lanes 2 and 6=Western blot using an in-house
produced antiserum against TTR50–127 that detects C-terminal frag-
ments; lane 3=Western blot using an in-house produced antiserum
against TTR24–35 that detects fragments containing position 30; lane
4=Western blot using commercial α-TTR antibodies (Dako), which do
not recognize the fragmented ATTR species [12]
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in wtATTR proportion was found between the two types
when heart tissue from non-transplanted patients was
examined, as the fraction of wtATTR consistently was
higher in fibril type A. In fact, the wild-type molecules
even dominated in amount over the mutant protein in this
type of fibrils, suggesting that the former molecules
actually are more easily incorporated than the latter. This
renders into speculations that the rate of fibril incorporation
actually might be accelerated after LT, as the supply of the
most easily added species thereby is increased. Even if this
Fig. 3 Proportion of wild-type molecules among full-length ATTR
species in cardiac amyloid fibrils, grouped according to fibril
composition type. Each measure point represents one individual. The
horizontal lines represent the mean value±SD for each group. Fibrils
composed of a mixture of full-length and fragmented ATTR consisted
of a higher proportion wild-type ATTR than fibrils composed of only
full-length ATTR. The difference between the groups is highly
significant, p=0.008
Fig. 2 Typical examples of
mass spectra obtained from
MALDI-TOF mass spectrome-
try analysis of adipose tissue
amyloid fibrils from a non-
transplanted (a) and transplanted
(b) patient. The tryptic peptides
ATTR22–34 containing valine
(wt) or methionine in non-
oxidized (m), mono-oxidized
(m (m-ox)), or di-oxidized
(m (d-ox)) state in position 30
are marked. The height of the
peaks was used as a relative
measure of quantity. Peaks
corresponding to non-oxidized
and mono-oxidized mutant
peptides were combined to
obtain the quantity of mutant
protein. The peak corresponding
to the di-oxidized peptide was
either absent or negligible in
size. The proportion of wt to
total ATTR was determined to
be 34% in A and 95% in B
Fig. 4 Proportion of wild-type molecules among full-length ATTR
species in adipose amyloid fibrils. The samples are grouped according
to fibril composition type and whether the patients have undergone
liver transplantation or not. Each measure point represents one
individual. The horizontal lines represent the mean value±SD for
each group. Fibrils from transplanted patients contained a higher
proportion of wild-type ATTR than samples from non-transplanted
patients regardless of fibril composition (p=0.002 and 0.0001). A
significant difference between the two fibril types was only seen
among transplanted patients (p=0.02)
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incorporated into fibrils of type A than type B. It, therefore,
seems possible that patients of type A are more susceptible
than those of type B for progressive amyloid deposition in
cardiac tissue after LT.
A higher content of wtATTR among patients having
fibrils with fragmented ATTR was probably also found by
Koike et al. [31]. They reported that fibrils with a weak and
non-glittering kind of birefringence after Congo red stain-
ing had a higher wild-type percentage than fibrils with a
strong and glittering birefringence, and it has been shown
before that there is a strong relationship between a fibril
composition with fragmented ATTR and a non-glittering
appearance of the fibrils [9].
It should be noted that the relative amount of wtATTR
found in the cardiac amyloid of the present study and
especially the values obtained for the fragment-containing
fibrils are unusually high compared to previous studies by
others on ATTRV30M [2, 17] as well as other mutations [2,
11, 16, 33]. On the other hand, two of the samples used in
the present study have been analyzed earlier by Edman
degradation, and this technique also gave a similarly high
wild-type content [30].
Amyloid turnover
Another issue raised by the results of the present study is
the occurrence of turnover of the amyloid deposits. The fact
that the proportion of wtATTR in transplanted patients was
very high even after a fairly short time after LT, suggests
that a quite rapid turnover of the deposits occurs. The
amyloid amount was not assessed in this study, but as the
increase in amyloid load would have to be immense to
account for the massive increase in wild-type percentage, it is
not likely to be the explanation. Also, follow-up reports
demonstrate that the amyloid mass in adipose tissue does not
seem to increase after LT, at least not to such extent [3, 22].
It can of course not be excluded that the latest added
subunits also most easily detach from the amyloid, thereby
producing a higher wild-type proportion than what is
representative for the whole material. The lower values of
wild-type proportion seen among transplanted type B
patients when the tissue was treated with guanidine–HCl
compared to non-treated specimens might be in line with
this. On the other hand, such effect of guanidine–HCl
treatment was not seen in amyloid from type A patients,
which still showed an almost complete dominance of wild-
type molecules.
Regardless if guanidine–HCl was used or not, a
difference in proportion of wtATTR was present between
the two fibril type groups among transplanted patients. The
fact that a similar divergence was not seen among non-
transplanted individuals is not easily interpreted, but a
higher turnover rate among type A patients can perhaps be
an explanation.
Fragmented versus full-length ATTR species
The V30M mutation is situated outside the C-terminal
fragments, which in many cases are the main constituent of
the fibrils. Therefore, a majority of the fibril components
can, unfortunately, not be included in the analysis. The
higher wild-type proportion seen among the fragment-
Fig. 5 Correlation between time elapsed after liver transplantation
and proportion of wild-type molecules among full-length ATTR
species in adipose amyloid fibrils. Each measure point represents
one individual. Black square, fibrils with fragmented ATTR (type A);
black triangle, fibrils without fragmented ATTR (type B). The figure
shows that the higher percentage of wild-type ATTR found among
fragment-containing fibrils is not due to longer duration after
transplantation among these patients compared to the patients lacking
fragments. A possible correlation between wt proportion and duration
after LT is seen within each fibril type group (r=0.99, p=0.003 for
type A and r=0.52, p=0.05 for type B), but not when both groups are
combined (r=0.36, p=0.1)
Fig. 6 Correlation between wild-type proportion among full-length
and fragmented ATTR species. Each measure point represents one
individual. White square, adipose tissue from non-transplanted
patients; black square, adipose tissue from transplanted patients; white
circle, cardiac tissue from non-transplanted patients; black circle,
cardiac tissue from transplanted patient (r=0.94, p=0.0001)
178 J Mol Med (2011) 89:171–180containing fibrils could thus in reality be an effect of
selective cleavage of the mutant molecules over the wild-
type molecules. The few existing studies where the wild-
type proportion is measured in both full-length ATTR and
C-terminal fragments separately imply, however, that the wt
proportion is similar in both species [11, 33]; however,
these investigations are based on other mutations and
mutational differences in cleavage propensity might exist.
In this study, we found that the wild-type proportion
among the investigated fragments approximately followed
the values of the full-length molecules. This implies that wt
and mutant protein are equally likely to be truncated, but it
should be kept in mind that it is not known if the wild-type
proportion among the investigated fragments (those that
contain position 30) reflects the wild-type proportion
among the much more abundant C-terminal fragments.
Time point and importance of TTR fragmentation
A correlation between fibril composition and clinicopatho-
logical features has also been reported in AA-amyloidosis
patients [34]. Why different types of amyloid fibrils are
seen in AA and ATTRV30M amyloidosis is far from
understood. Issues such as time of precursor cleavage
(before or after fibril incorporation) and potential impor-
tance of fragmentation in triggering fibrillogenesis are still
to be answered.
When the wt proportion was compared between full-
length and fragmented ATTR in the present study, a slightly
higher value among the former than the latter species was
found in transplanted patients, whereas the opposite was
true for non-transplanted patients. The implication of this is
uncertain, but interestingly, this pattern is consistent with
what would be expected if cleavage occurs after fibril
incorporation. In such case, the wt proportion in trans-
planted patients would always be somewhat higher among
full-length than fragmented species, as the most newly
incorporated subunits (which after LT always will be wt
molecules) would not have been cleaved yet.
However, the fact that several patients in this study had
been ill for 10–17 years and still showed no sign of
fragmented ATTR strongly suggests, that cleavage is not
occurring after fibril incorporation in all individuals with
time. Instead, variations in, for example, enzyme repertoire
or amyloid fibril associated molecules (serum amyloid P
component, heparan sulfate, etc.) could explain the differ-
ences between patients. Another possibilityisthatfull-length
TTRcouldformtwostructurallyandmorphologicallydistinct
fibrils, where exposure of the cleavage site occurs in one
of the structures but not in the other. Perhaps age-related
conditions of the extracellular environment render the
formation of one or the other form, which then is
sustained throughout the lifetime of the individual.
Structural polymorphism of amyloid-like fibrils formed
from a single precursor molecule has been reported for
several different proteins in vitro, for example Aß1–40
and IAPP [35], and the awareness of this phenomenon is
increasing. Whether it is commonly occurring also in vivo
deserves further attention.
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